increase purchasing power. SEC therefore proposes the inclusion of additional securities classes for margin lending by securities company to the customer for investments apart from listed securities. Such
SEC plans to review the operation system that the securities business operators and derivative contract business operators have adopted for some time in the operation and provision of services in order that the operation system will be more appropriate and flexible and in line with various types of business models. The operation system will also reduce burdens and obstacles in the business operations, with a view to grouping the relevant regulations of the operation system and the provisi...
general shareholders’ meeting on 23 February 2024 and exercise their voting rights on a proposed capital increase to be offered to the existing shareholders in proportion to their shareholding (rights
Today, development of technology is rapid and continuous. It disrupts development of services in the capital market. However, SEC views that many provisions in the Securities and Exchange Act B.E. 2535 (1992) and the Derivatives Act B.E. 2546 (2003) do not keep pace with these rapidly changing environments which may unintentionally limit the area that business operators can make use of technology, such as provision that requires business operators to disclosure its financial statements to...
sales revenue increased from THB 355.2 million to THB 374.3 million, respectively, representing an increase of 5.4%. The increase in sales revenue mainly due to higher sales revenue of our existing
of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27 Notification of the resignation of Chairman of the Audit
Committee, Appointment of Audit Committee, Appointment of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug